This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leonard, G. D. Articles by Kemeny, N. E. Search for Related Content PubMed PubMed Citation Articles by Leonard, G. D. Articles by Kemeny, N. E. Social Bookmarking                            What's this?

Neoadjuvant Chemotherapy Before Liver Resection for Patients With Unresectable Liver Metastases From Colorectal Carcinoma

From the Memorial Sloan-Kettering Cancer Center, New York; and Rabin Medical Center, Beilinson Campus, Petah-Tiqva, Israel

Address reprint requests to Nancy Kemeny MD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; e-mail: KemenyN{at}mskcc.org

Colorectal carcinoma is one of the most common cancers in the world, and more than 50% of these patients develop liver metastases. Despite recent advances, systemic chemotherapy for metastatic disease without the use of surgery is considered palliative, as there are rarely long-term survivors. However, patients who are candidates for surgical resection of their liver metastases can have a prolonged survival or possibly a cure. Consensus guidelines on criteria for resection and prognostic scores help facilitate patient selection, yet only 25% of patients with liver metastases are considered to have resectable metastases. Neoadjuvant chemotherapy has been explored in an attempt to render more patients candidates for resection. First reports using neoadjuvant systemic chemotherapy in patients with unresectable disease found that 13% to 16% of patients could be rendered resectable. Efforts to increase response rates using hepatic arterial infusion or biologic agents may increase resection rates. This review summarizes the current data on neoadjuvant chemotherapy, the rationale for this approach, potential complications, and future prospects.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. Zhao, J. Zhu, X. Ji, J. Cai, F. Wan, Q. Li, B. Zhong, S. Tucker, and D. Wang A Phase II Study of Irinotecan and Capecitabine for Patients with Unresectable Liver-only Metastases from Colorectal Cancer Jpn. J. Clin. Oncol., September 22, 2009; (2009) hyp114v1. [Abstract] [Full Text] [PDF]

				Z. MORISE, A. SUGIOKA, Y. TANAHASHI, Y. OKABE, M. IKEDA, T. KAGAWA, and C. TAKEURA Treatment of Patients with Unresectable Advanced Carcinoma of Biliary Tract - Chemotherapy and Surgical Resection Anticancer Res, May 1, 2009; 29(5): 1783 - 1786. [Abstract] [Full Text] [PDF]

				M. T. Lee, J. J. Kim, R. Dinniwell, J. Brierley, G. Lockwood, R. Wong, B. Cummings, J. Ringash, R. V. Tse, J. J. Knox, et al. Phase I Study of Individualized Stereotactic Body Radiotherapy of Liver Metastases J. Clin. Oncol., April 1, 2009; 27(10): 1585 - 1591. [Abstract] [Full Text] [PDF]

				S. R. Alberts and L. D. Wagman Chemotherapy for Colorectal Cancer Liver Metastases Oncologist, October 1, 2008; 13(10): 1063 - 1073. [Abstract] [Full Text] [PDF]

				S. Mocellin and D. Nitti In Reply J. Clin. Oncol., June 1, 2008; 26(16): 2789 - 2790. [Full Text] [PDF]

				R. L. Mahtani and J. S. Macdonald Synergy Between Cetuximab and Chemotherapy in Tumors of the Gastrointestinal Tract Oncologist, January 1, 2008; 13(1): 39 - 50. [Abstract] [Full Text] [PDF]

				J. Tabernero, E. Van Cutsem, E. Diaz-Rubio, A. Cervantes, Y. Humblet, T. Andre, J.-L. Van Laethem, P. Soulie, E. Casado, C. Verslype, et al. Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer J. Clin. Oncol., November 20, 2007; 25(33): 5225 - 5232. [Abstract] [Full Text] [PDF]

				R. A. Herbertson, S. T. Lee, N. Tebbutt, and A. M. Scott The expanding role of PET technology in the management of patients with colorectal cancer Ann. Onc., November 1, 2007; 18(11): 1774 - 1781. [Abstract] [Full Text] [PDF]

				L Rubbia-Brandt, E Giostra, C Brezault, A. Roth, A Andres, V Audard, P Sartoretti, B Dousset, P. Majno, O Soubrane, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery Ann. Onc., February 1, 2007; 18(2): 299 - 304. [Abstract] [Full Text] [PDF]

				L. Leichman Neoadjuvant Chemotherapy for Disseminated Colorectal Cancer: Changing the Paradigm J. Clin. Oncol., August 20, 2006; 24(24): 3817 - 3818. [Full Text] [PDF]

				S. Benoist, A. Brouquet, C. Penna, C. Julie, M. El Hajjam, S. Chagnon, E. Mitry, P. Rougier, and B. Nordlinger Complete Response of Colorectal Liver Metastases After Chemotherapy: Does It Mean Cure? J. Clin. Oncol., August 20, 2006; 24(24): 3939 - 3945. [Abstract] [Full Text] [PDF]

				G. Chong and D. Cunningham Improving Long-Term Outcomes for Patients With Liver Metastases From Colorectal Cancer J. Clin. Oncol., December 20, 2005; 23(36): 9063 - 9066. [Full Text] [PDF]